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Abstract--The ability of human placental glutathione S-transferase (GSHTr) to metabolize methyl 
parathion (MeP) was examined. MeP was found to be a substrate for both partially purified pre-term 
and highly purified term placental GSHTr. The characterization of the reaction by high performance 
liquid chromatography revealed the presence of desmethyl parathion (DesMeP) as the sole metabolite. 
Term placental GSHTr activity towards MeP ranged from 2.22 to 3.53 nmoles DesMeP formed, rain 
.mg ~ while an activity of 0.60 to 1.12 nmoles DesMeP formed • min -~ . mg -~ was observed with the 
pre-term placental enzyme. The absence of the O-dearylation reaction by pre-term and term placental 
GSHTr represents a major species- and/or tissue-specific difference. 
In the past few years, OPs§ have replaced the per- 
sistent organochlorine pesticides. Residues of OPs 
are now found in the water [1] and the food we 
consume [2, 3]. Other sources of exposure include 
the work environment [4], transfer from con- 
taminated laundry equipment [5], and drift from 
aerial application [6]. Reports have documented the 
exposure of a pregnant women [7] and transplacental 
passage [8] of OPs. 
MeP was selected as the representative of OPs 
because: (1) it is used extensively (present in 609 
EPA registered formulations); (2) transplacental 
passage of MeP has been shown in rats [9, 10]; (3) 
MeP is both embryotoxic [9] and teratogenic in 
laboratory animals [11, 12]; and (4) several inves- 
tigators, using various in vitro test systems, have 
demonstrated that MeP alone or in combination 
with other OPs is mutagenic [13-16]. Chromosomal 
aberrations have also been reported in pesticide for- 
mulators and applicators exposed to MeP [17, 18]. 
These reports on reproductive and genetic toxicity 
raise serious questions regarding the safety of the 
human conceptus from maternal exposure to MeP. 
It has been shown repeatedly that human placenta 
contains very little cytochrome P-450 and minimal 
cytochrome P-450-mediated monooxygenase activity 
toward specific xenobiotics [19]. Consequently, the 
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activation of MeP to the corresponding oxon or the 
oxidative formation of p-nitrophenol is expected to 
be negligible. In contrast, a high titer of GSHTr is 
known to be present in human placenta [20, 21]. 
Hence, the predominant pathway of biotransform- 
ation of MeP is most likely to proceed via conjugation 
with GSH. GSHTr-mediated metabolism represents 
a major in vivo detoxification pathway in mammals 
and is the subject of several reviews [22, 23]. A vast 
amount of information has been amassed on GSHTr 
reactions with OPs; however, not a single study to 
date has addressed the in vitro GSHTr-dependent 
biotransformation of MeP by human tissues. Since 
previous studies on human placental GSHTr have 
been restricted to model compounds [20, 21], its 
potential for possible metabolism of pesticides has 
never been explored. Therefore, our investigation 
has focused on the human placental metabolism of 
MeP, in order to gain an understanding of the poten- 
tial human fetotoxicity of OPs. 
Hollingworth et al. [24] suggested the involvement 
of different isozymes of rat hepatic GSHTr in the 
biotransformation of OPs. Subsequent studies 
[25, 26] have demonstrated that MeP can undergo 
O-dealkylation and/or O-dearylation by different 
isozymes purified from rat liver. Therefore, it 
appears that the type of reaction observed is depen- 
dent upon the form of GSHTr. Although both these 
reactions are generally considered as important in 
vivo detoxification pathways [27, 28], formation of a 
metabolite containing a p-nitrophenolic moiety by 
dearylation may represent an activation reaction, 
since phenolic compounds have been reported to be 
teratogenic [29]. 
Therefore, the present study was undertaken to 
determine whether MeP is a substrate for human 
placental GSHTr and to examine the types of reac- 
tion MeP may undergo. Preparations of highly 
purified, homogeneous term placental GSHTr [30] 
and partially purified pre-term GSHTr were used in 
these studies. 
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MATERIALS AND METHODS 
MeP (O,O-dimethyl O-p-nitrophenyl phosphor- 
othioate) was provided gratis by the Monsanto Co. 
(St. Louis, MO). DesMeP (O-methyl O-p-nitro- 
phenyl phosphorothioic acid) was synthesized 
according to the method of Whetstone et al. [31]. 
Para-phenylphenol was procured from Eastman 
Organic Chemicals (Rochester, NY).  GSH was 
obtained from United States Biochemical (Cleve- 
land, OH).  Sodium acetate (HPLC grade) was pur- 
chased from Fisher Scientific (Livonia, MI). CDNB 
was procured from Aldrich (Milwaukee, WI). All 
other chemicals were obtained commercially. 
Enzyme isolation. Pre-term placentas were 
obtained following early second trimester abortions. 
The procedure was performed surgically (dilatation 
and evacuation) under general and local anesthesia. 
Samples were placed immediately on ice and pro- 
cessed within 2 hr of pregnancy termination. Sub- 
sequent procedures were carried out at 4 ° unless 
specified otherwise. The tissues were weighed, 
minced, and washed several times with 50 mM Tris 
buffer, containing 0.25 M sucrose, pH7.4  (Buffer 
A),  to remove residual blood components. A 20% 
homogenate in Buffer A was centrifuged at 100,000 
g for 60 min. The post-microsomal supernatant frac- 
tion containing GSHTr was further purified by affin- 
ity chromatography, using a Sepharose 4B-GSH 
affinity column (1.3 x 4.0cm) as previously 
described [30]. Term placentas were obtained at the 
time of elective Cesarean deliveries. The purification 
of term placental GSHTr was performed as pre- 
viously described [30]. The enzyme preparations 
used were found to be apparently homogeneous 
(Fig. 1) by polyacrylamide gel electrophoresis [30]. 
Enzyme assay. The ability of partially purified 
human pre-term and purified term placental GSHTr 
to metabolize MeP was examined. The incubation 
mixture (0.5 ml) consisted of 0.25 mM MeP, 4 mM 
GSH, and 150/*g GSHTr in 0.1 M potassium phos- 
phate buffer, pH 7.4. The reaction was allowed to 
proceed at 37 ° for 30 min. The incubation vessel was 
placed on ice to terminate the reaction. Control 
assays were performed with boiled GSHTr. In the 
inhibition studies, prior to the addition of GSH and 
initiation of the reaction with MeP, GSHTr was 
preincubated with the specific inhibitor for 3 rain at 
37 ° in order to eliminate any possible interaction of 
GSH with the inhibitor. Protein content of placental 
cytosol was determined according to the method of 
Lowry et al. [32], whereas the dye binding assay of 
Bradford [33] was used to determine that of affinity 
and HPLC-purified GSHTr preparations. In the 
purification experiments, GSHTr activity towards 
CDNB was determined as previously described [30]. 
HPLCanalysis.  Once the reaction was terminated, 
10/.d of internal standard, p-phenylphenol (0.5 mg/ 
ml), was added to the incubation mixture and a 20-1tl 
aliquot of the reaction mixture was analyzed by 
HPLC. An Altex model 420 microprocessor equip- 
ped with two Isco model 825 metering pumps, a 
Rheodyne model 7125 sample injector, and a Spec- 
troMonitor III variable UV detector, set at 277 nm, 
was used. Separation was achieved with a Hamilton 
PRP-1 column (4.1 × 150mm) maintained at 40 ° 
with a circulating bath. The mobile phase consisted 
of 50 mM acetate buffer, pH 4.0, and MeOH. MeP 
and DesMeP were resolved using a MeOH gradient 
(54-100%). The elution program employed was as 
follows: a flow rate of 1 ml/min and 54% MeOH at 
time 0; percent MeOH was increased to 100 in 2 rain. 
beginning at time 8 min; flow was increased to 1.7 ml/ 
rain in 0.2 min at 9 min; and re-equilibration began 
at 18min, at which time the percent MeOH was 
decreased to 54 over 2 min and the flow rate was 
further increased to 2 ml/min and maintained for 
7.6 min. The amount of DesMeP produced was cal- 
culated from standard curves generated by plotting 
the ratios of peak height of DesMeP to p-phenyl- 
phenol versus the concentrations of DesMeP. 
Fig. 1. Polyacrylamide gel electrophoresis of term placental 
glutathione S-transferase. A 100ug protein sample of 
purified placental GSHTr was applied. 
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Fig. 2. High performance liquid chromatographic analysis of methyl parathion. (I) Elution profile of 
standards used: (A) DesMeP, 0.6 nmoles; (B) p-pheylphenol, 1.5 nmoles; and (C) MeP, 1.4 nmoles. 
(II) HPLC analysis of human placental glutathione S-transferase-catalyzed MeP metabolism. The 
reaction mixture consisted of 0.25 mM MeP, 4 mM GSH, and 150 #g GSHTr in 0.5 ml of 0.1 M potassium 
phosphate buffer, pH 7.4. The reaction was allowed to proceed at 37 ° for 30 min, at which time 
the reaction was terminated by placing the vessel on ice. After the addition of internal standard, 
p-phenylphenol, a 20-/A aliquot of the reaction was subjected to HPLC analysis. 
RESULTS 
The chromatographic  profiles of standard com- 
pounds and of the MeP utilized and D e s M e P  pro- 
duced by placental  G S H T r  are presented in Fig. 2. 
The respective re tent ion t imes (mean - S.E.)  for the 
standard compounds  were 3.30 -+ 0.04 for DesMeP  
(A),  13.40---0.14 for p-phenylphenol  (B), and 
14.55 --+ 0.13 min for MeP (C). The peaks observed 4s 
in the H P L C  profile of the incubation mixture con- 40 
taining G S H T r  were 3.4, 13.2, and 14.6 min. H P L C  
analysis indicated the presence of a single metaboli te .  ~ 3~ 
This metabol i te  was identified as DesMeP,  based on ~ 30 
similar re tent ion time. The 1 : 1 ratio observed in the a 
disappearance of MeP and formation of DesMeP  ~ 2s 
confirms D e s M e P  as the sole metabol i te  of the term ~ 20 
placental GSHTr-ca ta lyzed  reaction. No DesMeP ~, 
product ion was observed when boiled G S H T r  was ~ 1~ 
used. lo 
In the presence of 0.25 mM MeP and 4 mM GSH,  
the term placental GSHTr -med ia t ed  reaction was 
found to be l inear up to 60min  (Fig. 3), with a o 
0.99 coefficient of  determinat ion.  Since measurable  
amounts  of D e s M e P  were detected,  a 30-min incu- 
bation t ime was selected for subsequent  experiments.  
Protein dependency  of the reaction is shown in Fig. 
4. Regression analysis of D e s M e P  product ion versus 
amount  of G S H T r  used exhibited a linear relation- 
ship (coefficient of determinat ion = 0.99). 
Term placental G S H T r  activity toward MeP is 
presented in Table 1. The  specific activity ranged 
from 2.22 to 3.53 nmoles DesMeP  f o r m e d ,  min -1 • 
mg -1, suggesting relatively minor  inter-individual 
differences in the G S H T r  activity when purified prep- 
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Fig. 3. Time dependency of human placental glutathione S- 
transferase-mediated O-dealkylation of methyl parathion. 
Assay conditions were 0.25 mM MeP, 4 mM GSH, 1.05 mg 
enzyme in 3.5 ml of 0.1 M potassium phosphate buffer, 
pH 7.4. The reaction mixture was incubated at 37 °. A 500-~1 
aliquot was taken at the prescribed intervals and analyzed 
by HPLC. 
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Table 1. Activity of purified term placental glutathione S- 
transferase toward methyl parathion 
Sample Specific activity 
No. {nmoles DesMeP formed, min ' . mg 1) g 
1 3.27 ,~ 
2 3.53 o 




"6 7 2.95 zE 
8 3.24 
Mean _+ S.E, 2.92 _+ 0.14 
Assays were performed as described in Materials and 
Methods. 
Table 2 depicts the kinetic parameters  of term 
placental G S H T r  for MeP and GSH.  Representa t ive  
L ineweave r -Burk  plots of the kinetic data (Sample 
1, Table  2) are shown in Figs. 5 and 6. G S H  con- 
centrat ion was kept constant at 4 m M  for deter- 
mination of K,,, and Vma× for MeP.  At  a MeP con- 
centrat ion of 0.25 mM,  K,,, and Vmax values for G S H  
were assessed. The  K,,, of MeP ranged from 0.20 to 
0.51 raM, while the Km of G S H  varied from 0.49 to 
0.66 mM. The Vma × of MeP was more than twice that 
of G S H ,  suggesting that the concentrat ion of MeP 
has a greater  effect on the rate of reaction than GSH.  
The in vitro inhibition of term placental GSHTr-  
media ted  metabol ism of MeP by inorganic heavy 
metals is given in Table 3. Based on preliminary 
experiments ,  inhibitor concentrat ions were chosen 
to produce about  50% inhibition. Cupric chloride 
appeared to be the most effective inhibitor,  since a 
4-fold lower concentra t ion of cupric chloride resulted 
in about  the same level of inhibition observed at 
1.0 mM mercuric  chloride or  cadmium chloride. The 
observed inhibition caused by all three metals was 
statistically significant (P ~< 0.05) as compared  to 
control.  
The results of the purification of G S H T r  from 
human pre- term placenta are given in Table 4. The 
number  of samples examined thus far reflect the 
norm and variation in placental G S H T r  activity at 
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Fig. 4. Protein dependency of human placental glutathionc 
S-transferase-mediated O-dealkylation of methyl para- 
thion. MeP and GSH concentrations were maintained at 
0.25 and 4 mM, respectively, while the amount of enzyme 
was varied as indicated. See text for further details. 
activity of  0.47 -+ 0.06/*moles . min i . mg J was 
observed towards C D N B  with the crude fractions. 
The average specific activity of the 4B-GSH fractions 
was 91.68 - 12.52/*moles • rain 1 . mg- l .  A sub- 
stantial, overall  purification of 220-fold was achieved 
using affinity chromatography alone. Recovery  of 
enzymatic activity averaged about 75%. 
MeP metabol ism studies were also conducted with 
pre- term placental  G S H T r  (Table 5). H P L C  analysis 
showed the product ion of a single metaboli te.  
DesMeP,  indicating quali tat ive similarity between 
pre- term and term placental G S H T r  in the metab- 
olism of MeP.  Data  also suggest that pre-term pla- 
centa is capable of significant biotransformation of 
MeP. It must be noted that pre- term G S H T r  prep- 
arations used were partially purified by affinity 
chromatography,  due to lack of sufficient material 
for further purification by HPLC.  In view of this, a 
direct comparison of term and pre- term activities 
toward MeP is precluded. 
D I S C U S S I O N  
Accurate  assessment of MeP metabol ism can only 
be accomplished with specific and sensitive assays. 
the corresponding gestational periods. An overall  Most of the procedures  previously used to quantitate 
Table 2. Kinetic parameters of term placental glutathione S-transferasc 
Methyl parathion Glutathione 
Vmax Vma x 
Sample K,, (nmoles DesMeP K,, (nmoles DesMeP 
No. (mM) formed, min i . mg-1) (mM) formed, min t. mg ~) 
1 0.47 9.52 0.62 4.21 
2 0.30 5.46 0.66 3.68 
3 0.51 8.07 0.51 2.57 
4 0.20 4.58 0.49 2.71 
Mean + S.E. 0.37 -+ 0.07 6.91 + 1.14 0.57 -+ 0.04 3.29 -+ 0.39 
See text tk~r further details. 
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Fig. 5. Effects of methyl parathion concentration on the O-dealkylation activity of term placental 
glutathione S-transferase. Assays were performed in the presence of 4 mM GSH, 150 #g enzyme, and 
the indicated concentrations of MeP, as specified in Materials and Methods. 
the biotransformation of MeP were based on either 
radiometry [34, 35] or gas-liquid chromatography 
[36, 37]. Besides being cumbersome and time con- 
suming, these methods possess certain inherent prob- 
lems, such as sample loss related to efficiency of 
extraction and tedious sample clean-up. A spectro- 
photometric assay for MeP has been reported [38], 
but it was not reproducible in our hands. Therefore, 
the HPLC method was devised, which allowed a 
direct measurement of both substrate depletion and 
product formation. Furthermore, the metabolite is 
amenable to further analysis. The HPLC method is 
extremely sensitive with lower limits of detection 
for DesMeP in the pmole range. Moreover, sample 
clean-up prior to analysis, the use of radiolabeled 
substrate, and laborious methodology are elimi- 
nated. 
Recent studies [39, 40] have reported that pla- 
cental GSHTr activity is not altered following 
exposure of pregnant women to the constituents of 
cigarette smoke. Animal studies have also indicated 
that placental GSHTr is refractory to the effects of 
such inducers as trans-stilbene oxide [41], pheno- 
barbital, butylated hydroxyanisole, 2-acetylamino- 
fluorene, and 3-methyl-4-dimethylaminoazobenzene 
[42]. These results suggest that the induction of 
human placental GSHTr upon exposure to xeno- 
biotics is questionable. In addition, the reported 
presence of a single form of human placental GSHTr 
[20, 21, 30] would negate possible, selective induc- 
tion of certain isozymes. Hence, exposure of preg- 
nant women to xenobiotics is acknowledged, but is 
not of paramount concern in this study. 
In contrast to the low cytochrome P-450-mediated 
• 6 0  T 
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Fig. 6. Effects of glutathione concentration of the O-dealkylation activity of term placental glutathione 
S-transferase. Assays were performed in the presence of 0.25 mM MeP, 150 ~g GSHTr, and the indicated 
concentrations of GSH. See text for further details. 
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Table 3. Inhibition of term placental glutathione S-transferase-mediated metabolism of methyl 
parathion by various heavy metals 
% Inhibition 
Sample Control 1 mMHgCI2 1 mMCdCI2 0.25 mMCuCI2.2H20 
1 0.0 45.2 49.0 49.0 
(3.00) (1.65) (1.53) (1.53) 
2 0.0 34.7 45.6 49.5 
(2.95) (1.93) (1.61) (1.49) 
3 0.0 52.6 50.4 51.0 
(3.24) (1.53) (1.61) (1.59) 
Mean ± S .E.  44.2 ± 5.2 48.3 ± 1.4 49.8 ± 0.6 
(3.06 ~ 0.09) (1.70 ± 0.12)* (1.58 ± 0.03)+ (1.54 ~ 0.03)~ 
Specific activity values are expressed as nmoles DesMeP formed, min ~. mg -~ and are given in 
parentheses. Experiments were performed as described in Materials and Methods. 
* P ~ 0.05 as compared to control. 
t P ~< 0.005 as compared to control. 
Table 4. Purification of human pre-term placental glutathione S-transferase by affinity 
chromatography 
Gestation Crude 4B-GSH % 
(weeks) N spec. act.* spec. act.* Purification+ Recoveryt 
13 1 0.44 65.18 149 93 
14 1 0.33 36.97 112 149 
15 4 0.49 m 0.08 74.38 ± 26.43 153 68 
16 6 0.62 ± 0.26 126.13 ± 43.61 246 61 
17 1 0.50 135.94 271 110 
18 2 0.32 70.03 236 76 
19 2 0.27 104.15 405 65 
20 1 0.26 35.00 135 45 
21 1 0.67 65.80 98 91 
23 1 0.37 92.13 252 65 
See text for further details. 
* Expressed in /~moles CDNB conjugate formed-min a.mg ~ (mean -+ S.E., 
applicable). 
+ Reported as an average whenever applicable. 
when 
Table 5. Pre-term placental glutathione S-transferase 
activity toward methyl parathion* 
Specific activity 
Sample Gestation (nmoles DesMeP 
No. (weeks) formed, rain -l . mg -l) 
1 15 0.85 
2 16 0.64 
3 16 0.72 
4 17 1.12 
5 18 0.99 
6 20 0.60 
7 23 0.82 
Mean -+ S.E. 0.82 -+ 0.07 
* Transferase was purified solely by affinity 
chromatography. 
monooxygenase  activity [19], the p lacenta  exhibi ts  
r a the r  subs tant ia l  G S H T r  activity [20,21].  The  
specific activity of the  part ial ly purif ied p re - t e rm 
placenta l  G S H T r  towards  C D N B  (Table  4) does  not  
differ statistically f rom tha t  of t e rm placenta  [30], 
a l though the crude  activity of p re - t e rm placenta  is 
approx imate ly  2.5-fold g rea te r  than  that  of t e rm [30], 
Two i n d e p e n d e n t  groups  [25, 26] have demon-  
s t ra ted  tha t  purif ied isozymes of rat  liver G S H T r  
can catalyze O-dea lky la t ion  a n d / o r  O-deary la t ion  of 
MeP,  suggest ing that  the na tu re  of the  t ransferase  
may be  respons ib le  for differences  in catalysis. The  
isozymes of rat  l iver G S H T r s  ob ta ined  by fur ther  
purif icat ion of f ract ion I [26], which did not  b ind  
the D E A E - c e l l u l o s e  and  are recognized  as basic 
isozymes [43, 44], were r epo r t ed  to catalyze >~ 98% 
of the  to ta l  me tabo l i sm of MeP  via O-dealkyla t ion .  
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In contrast, the fraction II isozymes [26], which did 
bind to DEAE-cellulose and are considered as acidic 
and//or neutral forms [45, 46], catalyzed both O- 
dealkylation and O-dearylation. The absence of the 
O-aryl conjugate suggests that placental GSHTr, an 
anionic protein, is catalytically different than the 
acidic and/or neutral forms of rat liver GSHTr. 
The data presented in this paper constitute the 
first report of purified human GSHTr-mediated 
metabolism of a commonly used insecticide, MeP. 
The average specific activity of 2.92 nmoles • min -1 
• mg-1 observed with term placental GSHTr toward 
MeP (Table 1) is comparable to the rates of 3.98 
nmoles • min -1 - mg -1 reported for purified rat liver 
GSHTr [25] and 1 .84nmoles .  min -1 .  mg -1 for 
Sephadex G-50 gel supernatant fraction of rat liver 
[35]. However, the placental GSHTr activity is 3.7- 
fold less than that reported by Motoyama and Dau- 
terman [26] for a presumably, basic isozyme of rat 
liver GSHTr. The observed activity of both term 
and pre-term placental (Table 5) GSHTr should be 
considered as significant, since extrahepatic metab- 
olism of MeP in the rat is only about 2-10% of that 
observed in liver [35]. 
The average Km for MeP calculated with placental 
GSHTr (Table 2) is consistent with the values of 0.51 
and 0.21 for mouse and sheep liver GSHTr [38] 
respectively. However, the mean Km value for GSH 
(Table 2) is approximately 2-3 times that reported 
for sheep and mouse liver GSHTr [38], suggesting 
major differences in the affinity of GSHTr from 
different sources for GSH. Comparison with values 
for human GSHTr is not possible due to lack of 
reported data. 
Exposure to each of the metal salts examined 
resulted in a statistically significant inhibition of term 
placental GSHTr (Table 3). Since term placenta 
contains a single form of GSHTr, it is possible to 
compare inhibition data obtained for MeP with those 
reported for CDNB [21]. The necessity of such a 
comparison arises from the fact that studies on OP 
metabolism by human placental GSHTr have not 
been reported. The results for cadmium chloride are 
consistent with the reported value [21]. However, the 
percent inhibition observed with mercuric chloride is 
50% less than that determined by Mannervik et al. 
[21]. Comparative data for cupric chloride were not 
available. Inhibition data support the contention that 
the cysteinyl residues of placental GSHTr are inte- 
gral to catalytic function [20]. 
This is also the first paper that reports the purific- 
ation of human pre-term placental GSHTr. A quali- 
tative change in human placental GSHTr during 
gestation has not been documented. However, con- 
sidering that one form exists in term placenta, the 
identical form is likely to be present in pre-term 
placenta. Besides the model compounds previously 
used [40, 47], the results of this study indicate that 
pre-term placental GSHTr can efficiently catalyze 
the metabolism of MeP. 
In this study, we have shown that pre-term and 
term placental GSHTr catalyze the O-dealklyation 
of MeP. This ability of the placenta may protect the 
human fetus from the deleterious effects of maternal 
MeP exposure during gestation. Term placental 
GSHTr may have been at least partially responsible 
for the lack of fetotoxicity observed in a pregnant 
worker acutely exposed to a combination of 
mevinphos and phosphamidon [7]. These com- 
pounds should also undergo similar placental metab- 
olism as MeP, since all are methyl ester OPs. 
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